Seres Therapeutics Inc (NASDAQ: MCRB)’s stock price has gone decline by -2.85 in comparison to its previous close of 0.89, however, the company has experienced a -7.41% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-12-16 that CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and Chief Executive Officer, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT.
Is It Worth Investing in Seres Therapeutics Inc (NASDAQ: MCRB) Right Now?
The 36-month beta value for MCRB is also noteworthy at 2.09. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MCRB is 124.81M, and at present, short sellers hold a 13.93% of that float. The average trading volume of MCRB on December 17, 2024 was 3.67M shares.
MCRB’s Market Performance
MCRB stock saw an increase of -7.41% in the past week, with a monthly gain of 57.29% and a quarterly increase of -17.66%. The volatility ratio for the week is 10.11%, and the volatility levels for the last 30 days are 13.07% for Seres Therapeutics Inc (MCRB). The simple moving average for the past 20 days is 1.10% for MCRB’s stock, with a -1.96% simple moving average for the past 200 days.
Analysts’ Opinion of MCRB
Oppenheimer, on the other hand, stated in their research note that they expect to see MCRB reach a price target of $12. The rating they have provided for MCRB stocks is “Outperform” according to the report published on June 26th, 2023.
JP Morgan gave a rating of “Neutral” to MCRB, setting the target price at $7 in the report published on April 21st of the previous year.
MCRB Trading at 9.41% from the 50-Day Moving Average
After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.82% of loss for the given period.
Volatility was left at 13.07%, however, over the last 30 days, the volatility rate increased by 10.11%, as shares surge +50.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.05% upper at present.
During the last 5 trading sessions, MCRB fell by -6.85%, which changed the moving average for the period of 200-days by -23.70% in comparison to the 20-day moving average, which settled at $0.8554. In addition, Seres Therapeutics Inc saw -38.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MCRB starting from DesRosier Thomas, who sale 878 shares at the price of $0.54 back on Nov 18 ’24. After this action, DesRosier Thomas now owns 135,192 shares of Seres Therapeutics Inc, valued at $475 using the latest closing price.
von Moltke Lisa sale 977 shares at $0.54 during a trade that took place back on Nov 18 ’24, which means that von Moltke Lisa is holding 32,415 shares at $528 based on the most recent closing price.
Stock Fundamentals for MCRB
Current profitability levels for the company are sitting at:
- -2214.05 for the present operating margin
- -108.88 for the gross margin
The net margin for Seres Therapeutics Inc stands at -398.05. The total capital return value is set at -1.24. Equity return is now at value -3758.21, with -60.50 for asset returns.
Currently, EBITDA for the company is -85.43 million with net debt to EBITDA at -0.19. When we switch over and look at the enterprise to sales, we see a ratio of 2724.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.12.
Conclusion
In summary, Seres Therapeutics Inc (MCRB) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
